You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Microglia and Cholesterol Handling: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor: Oscar M. Muñoz Herrera , Angela M. Zivkovic

Cholesterol is essential for brain function and structure, however altered cholesterol metabolism and transport are hallmarks of multiple neurodegenerative conditions, including Alzheimer’s disease (AD). The well-established link between apolipoprotein E (APOE) genotype and increased AD risk highlights the importance of cholesterol and lipid transport in AD etiology.

  • microglia
  • cholesterol
  • Alzheimer’s disease

1. Introduction

Since Alzheimer’s disease (AD) was first described by Alois Alzheimer over a century ago [1], it has been known that an aberrant accumulation of lipid “saccules” as they were called then, essentially an enrichment in intracellular lipids, is characteristic of the brain in AD. Since then researchers have gained a much more sophisticated understanding of how lipid accumulation and aberrant lipid metabolism contribute to the etiology of AD. It is now clear, for example, that cholesterol enrichment in the plasma membranes of neurons is causally linked to production of the cytotoxic amyloid beta (Aβ) peptide [2] through a lipid raft-dependent mechanism. Cholesterol is an essential lipid component for various cellular structures and organelles, and its trafficking occurs via various distinct pathways which include endocytosis/phagocytosis, transport to the plasma membrane and repurposing of cholesterol by removal from the plasma membrane [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Disruption in cholesterol transport and trafficking can lead to aberrant cellular function. For example, in Niemann-Pick Type C disease, which involves an autosomal recessive mutation causing neurodegeneration, aberrant cholesterol metabolism is linked to Aβ deposition similar to the pathology occurring in AD [18]. In mouse models hypercholesterolemia results in glial cell hyperactivation, accelerating amyloid pathology in the brain [19]. In zebrafish exposure to high cholesterol (4% weight/weight cholesterol) for 19 days resulted in higher brain mRNA expression of proinflammatory markers and elevated brain mRNA of cluster of differentiation molecule 11B, a microglia marker, in a type 2 diabetes model [20].
However, it is not yet clear whether unregulated cholesterol drives pathology or if cholesterol is simply worsening an already pathological process. Much more is known about the cholesterol-mediated regulation of cellular function in neurons and astrocytes in the context of AD [21][22][23]; however not as much is known about how microglia, the immune cells of the brain, respond to high cholesterol environments. Microglia are quickly emerging as key players in the pathophysiology of AD [24][25][26][27][28][29]. Genome-wide association studies have consistently found that genes expressed predominantly or exclusively in microglia in the brain, such as triggering receptor expressed on myeloid cells 2 and myeloid cell surface antigen CD33, are associated with AD risk [30][31][32][33][34].

2. Cholesterol-Mediated Regulation of Microglia Phenotype

Microglia are classically characterized as immune cells predominantly found in a homeostatic state, only moving outside of that resting or homeostatic phenotype to respond acutely to the infiltration of foreign and harmful substances [35][36]. However, recent studies have revealed that microglia are in fact very dynamic, occupying a diverse set of states, with different functional phenotypes [37][38]. Microglia perform different roles in different environments, falling into four broad categories: injury-response microglia, proliferative-region-associated microglia (PAM), disease-associated microglia (DAM), and lipid droplet-accumulating microglia. Injury-response microglia can be induced by lysolecithin injection in mice [39], which leads to the upregulation of lipoprotein lipase and apolipoprotein E (APOE) among other effects [39]. Microglia that surround oligodendrocytes during the first week after birth are highly phagocytic, identified as PAM, and share a very similar profile at the transcriptional level with DAM, such as the increased expression of lipid metabolic genes [40]. Researchers have identified the transition into the DAM state by the downregulation of typical microglia markers (e.g., C-X3-C motif chemokine receptor 1 and adenosine diphosphate receptor P2Y12) and the activation of phagocytic and lipid metabolic genes; as well as having overlapping signatures with injury-response microglia and PAM [39][40]. Elements of the DAM profile are highly conserved from PAM to DAM in mouse models [40][41], behaving with similar phenotypic states as PAM in the zebrafish model [42], indicating that both processes are highly regulated. Even though the murine DAM gene profile from an AD-inducible model is detected in human DAM, the majority of those genes are dispersed across multiple subgroups of microglia instead of being specific to DAM in humans, highlighting species-specific differences in microglia phenotype [43].
Lipids are essential to the brain for both structure and function [44]; however, an overload of lipids can lead to catastrophic damage. When lipid molecules in a given area surpass a critical concentration they begin to aggregate, form micelles, and even form crystals (e.g., cholesterol crystals), which then act as detergents and structures that lyse and otherwise damage cells and their components [45]. Thus, lipid storage and disposal mechanisms have emerged to protect cells from these extreme events. Cells usually respond to excess cholesterol by inducing the cholesterol efflux machinery, including APOE [46]. Although the cholesterol metabolism and regulation have been described thoroughly elsewhere [47]. Briefly, the sterol regulatory element binding protein family is involved in regulating genes involved in cholesterol synthesis, transport, and efflux. Induction of the sterol regulatory element binding protein transcriptional program in response to low or high concentrations of cholesterol detected in the endoplasmic reticulum membrane activates and deactivates, respectively, the transcription of genes involved in lipid biosynthesis and import vs. storage and efflux [48][49], including the expression of low-density lipoprotein receptor [48][50] for cholesterol import, and the adenosine triphosphate-binding cassette (ABC) family, in particular ABCA1, for cholesterol efflux [51][52][53]. However, when the capacity to utilize or efflux excess lipids has been surpassed all cells have the ability to form lipid droplets as a way to temporarily store the excess [54]. When the storage of lipids in lipid droplets becomes chronic and/or the number of lipid droplets starts to exceed the normal threshold, there can be effects on the ability of cells to perform their normal functions [55].
In the case of microglia, lipid droplet-accumulating microglia, or microglia that are characterized by lipid droplet accumulation, perform with a defective phagocytic phenotype [56]. Lipid droplet-accumulating microglia have an enhanced phagocytic uptake of lipid, exacerbating the lipid droplet accumulation burden, and promoting chronic and self-sustained microglial activation [57]. Sustained inflammation further pushes microglia into an activated state of hyperactivity, which creates a feedback that exacerbates neuroinflammation and damages blood–brain barrier integrity [58]. Whereas cholesterol excess leads to lipid droplet accumulation and chronic microglial activation, dysregulated cholesterol concentration in the opposite direction can also be problematic. For example, in mouse models with an interleukin-10 receptor knockout (specifically in astrocytes) there is prolonged neuroinflammatory response to peripheral lipopolysaccharide (LPS), with interleukin-10 receptor signaling deficits and a lack of cholesterol biosynthesis both leading to the inability to resolve microglial activation [59].

3. Cholesterol-Mediated Regulation of Microglia Function

One of the main functions of microglia is to remove debris and other cytotoxic molecules in a constant effort to maintain a homeostatic environment [37][60]. When microglia fail to perform this essential function a number of downstream effects can occur and lead to disease development. For example, the failure to keep up with the clearance of Aβ monomers contributes to the formation of Aβ oligomers and eventually plaques, which are a hallmark of AD pathophysiology [61][62][63].
One of the metabolic pathways, in addition to cholesterol efflux and storage, that can be activated in the presence of cholesterol is the generation of a variety of cholesterol metabolites, which in turn can either act as regulators of downstream pathways or have direct deleterious effects. Oxysterols are generated in animals, including humans, by enzymatic means as well as non-enzymatic means. Cholesterol can be oxidized to 25-hydroxycholesterol by cholesterol 25-hydroxylase, and to 27-hydroxycholesterol by sterol 27-hydroxylase [64]. While 25-hydroxycholesterol can also be generated by non-enzymatic oxidation by reactive oxygen species (ROS), 7-ketocholesterol is generated exclusively through non-enzymatic means, for example via oxidation by ROS [64]. Oxidized cholesterol is fundamental for generating a pro-inflammatory environment for microglia [65]. In rodent microglia, cholesterol oxides confer cytotoxic effects by potentiating the effects of LPS and nitric oxide production, promoting programmed cell death [66]. Specifically, 25-hydroxycholesterol was observed to induce the highest mRNA levels of nitric oxide synthase in combination with LPS in these cells [66]. Similarly, 27-hydroxycholesterol in vitro treatment of rodent microglia cell lines induced accumulation of ROS and the subsequent activation of the pro-inflammatory interleukin-6/signal transducer and activator of transcription 3 signaling pathway [67]. In turn, in the presence of increased ROS the proportion of sterols of non-enzymatic origin increases, and promotes a chronic DAM state [68]. Studies have also shown that 25-hydroxycholesterol can increase the area of the lipid bilayer as well as affecting the orientation of lipids within the membrane [69], increasing membrane permeability [70][71][72], which has a direct influence on cell death activation [73]. It has also been reported that 27-hydroxycholesterol can induce cellular senescence in microglia through oxidative damage [67][74][75], and that 7-ketocholesterol promotes cellular death by altering biogenesis and peroxisomal activity through oxidative stress [76][77]. Investigators report 7-ketocholesterol released during chronic inflammation indirectly induces neuronal damage mediated by activated microglial cells [78]. It is not yet clear how the relative and absolute concentrations of all of these cholesterol species impact overall microglial function and phenotype.
There is evidence that when microglia are unable to maintain proper cholesterol metabolism and lipid droplets accumulate a pro-inflammatory lipidomic profile emerges [79]. A number of approaches to reduce this cholesterol-induced microglia dysfunction have been investigated. The liver X receptor, which is induced by oxysterols, agonistically promotes an anti-inflammatory environment in the central nervous system (CNS) of rodent models and their primary microglia [80]. Liver X receptor-mediated suppression of inflammation and lipid recycling has also been shown to mitigate disease severity at the microglial level in rodent models [81]. These reports in rodent models suggest that reducing cholesterol via liver X receptor activation could be an approach for clearing the burden from microglia and restoring their functionality.
An additional way in which cholesterol can negatively impact microglia function is through mechanisms involving membrane proteins [82]. The enrichment of cholesterol in plasma membranes potentiates the formation of lipid rafts, which increases the physical proximity of raft-associated proteins. An example of how this can be detrimental when excessive is the case of overactivation via LPS. In a high-cholesterol membrane environment, monomers of Toll-like receptors are in close proximity to each other, enabling the formation of Toll-like receptor dimers, which in turn leads to pro-inflammatory signaling in response to activation by LPS [83]. In murine models chronic LPS activation leads to increased Aβ deposition [84][85].
A high cholesterol diet (3% cholesterol) has been shown to induce a pro-inflammatory profile in rodent microglia models by activating the inflammasome; anti-inflammatory cytokines are also secreted as part of the response, but the result is ultimately a damaged blood-brain-barrier [86]. Furthermore, the literature indicates that cholesterol load causes chronic inflammation in microglia [87]. A high fat, high cholesterol diet (21% fat), administered for 18 weeks increased the presence of interleukin-6 in the microglia and plasma of wild-type and APOE-/-mice [88]. The APOE4 isoform of APOE has been consistently associated with an increased risk for AD in genome-wide association studies [89]. The ApoE4 protein encoded by the APOE4 gene has been shown to have a significantly reduced capacity to induce cholesterol efflux from a variety of cell types compared to APOE3 [90]. In a human microglia cell line expressing APOE4 it was observed that excess cholesterol leads to higher levels of inflammation [91], highlighting that a reduced capacity to efflux cholesterol, particularly in an environment of excess cholesterol, is associated with microglial activation. Together, these findings suggest that a high cholesterol environment, particularly in genetically susceptible individuals with a reduced capacity to transport and efflux cholesterol (e.g., APOE4 carriers) leads to chronic microglia inflammation and activation, reducing the ability of microglia to respond to additional stressors.
In the CNS, increasing cholesterol leads to reduced phagocytosis by phagocytes [92], and conversely, depleting cholesterol with methyl-β-cyclodextrin increases phagocytosis. Depleting cholesterol using methyl-β-cyclodextrin enhanced phagocytic activity in primary rat microglia when treated with cholesterol and LPS [93]. Alternatively, one group reported that the accumulation of esterified cholesterol in microglia as a result of the dysfunction of the transmembrane structure triggering receptor expressed on myeloid cells 2, a receptor for lipidated ApoE and other lipids [94][95], did not evoke changes in their phagocytic capacities [96]; suggesting that the concern should not lie solely on the amount of cholesterol microglia are exposed to, but their capacity to traffic cholesterol accordingly. Moreover, microglia cultured from ABCA1 −B/−B mice, exhibit augmented LPS-induced secretion of tumor necrosis factor α (TNF-α) and decreased phagocytic activity hand in hand with decreased ABCA1/APOE expression, which are involved in cellular cholesterol efflux [46][97][98]. Loss-of-function of ABCA7, which also impairs the ability of microglia to efflux cholesterol, accelerated enzymatic activity on the amyloid precursor protein, impaired microglial Aβ clearance and impaired the ability of microglia to perform phagocytosis, contributing to the development of AD [99][100]. In a mouse AD model using a knockout of the protein translocator protein 18 kDa, a molecular sensor specific to glial cells in the brain, it was shown that there is increased Aβ deposition in the brain and a decreased number of microglia undergoing phagocytosis compared to control mice [101], highlighting the importance of effective microglial phagocytosis in the prevention of AD.

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10123105

References

  1. Hippius, H.; Neundörfer, G. The Discovery of Alzheimer’s Disease. Dialogues Clin. Neurosci. 2003, 5, 101–108.
  2. Wang, H.; Kulas, J.A.; Wang, C.; Holtzman, D.M.; Ferris, H.A.; Hansen, S.B. Regulation of Beta-Amyloid Production in Neurons by Astrocyte-Derived Cholesterol. Proc. Natl. Acad. Sci. USA 2021, 118, e2102191118.
  3. Chang, T.Y.; Chang, C.C.Y.; Harned, T.C.; De La Torre, A.L.; Lee, J.; Huynh, T.N.; Gow, J.G. Blocking Cholesterol Storage to Treat Alzheimer’s Disease. Explor. Neuroprot. Ther. 2021, 1, 173–184.
  4. Chang, T.-Y.; Yamauchi, Y.; Hasan, M.T.; Chang, C. Cellular Cholesterol Homeostasis and Alzheimer’s Disease. J. Lipid Res. 2017, 58, 2239–2254.
  5. Storch, J.; Xu, Z. Niemann-Pick C2 (NPC2) and Intracellular Cholesterol Trafficking. Biochim. Biophys. Acta 2009, 1791, 671–678.
  6. Pfeffer, S.R. NPC Intracellular Cholesterol Transporter 1 (NPC1)-Mediated Cholesterol Export from Lysosomes. J. Biol. Chem. 2019, 294, 1706–1709.
  7. Urano, Y.; Watanabe, H.; Murphy, S.R.; Shibuya, Y.; Geng, Y.; Peden, A.A.; Chang, C.C.Y.; Chang, T.Y. Transport of LDL-Derived Cholesterol from the NPC1 Compartment to the ER Involves the Trans-Golgi Network and the SNARE Protein Complex. Proc. Natl. Acad. Sci. USA 2008, 105, 16513–16518.
  8. Reverter, M.; Rentero, C.; de Muga, S.V.; Alvarez-Guaita, A.; Mulay, V.; Cairns, R.; Wood, P.; Monastyrskaya, K.; Pol, A.; Tebar, F.; et al. Cholesterol Transport from Late Endosomes to the Golgi Regulates T-SNARE Trafficking, Assembly, and Function. Mol. Biol. Cell 2011, 22, 4108–4123.
  9. Liscum, L.; Dahl, N.K. Intracellular Cholesterol Transport. J. Lipid Res. 1992, 33, 1239–1254.
  10. Yamauchi, Y.; Yokoyama, S.; Chang, T.-Y. ABCA1-Dependent Sterol Release: Sterol Molecule Specificity and Potential Membrane Domain for HDL Biogenesis. J. Lipid Res. 2016, 57, 77–88.
  11. Abi-Mosleh, L.; Infante, R.E.; Radhakrishnan, A.; Goldstein, J.L.; Brown, M.S. Cyclodextrin Overcomes Deficient Lysosome-to-Endoplasmic Reticulum Transport of Cholesterol in Niemann-Pick Type C Cells. Proc. Natl. Acad. Sci. USA 2009, 106, 19316–19321.
  12. Yamauchi, Y.; Iwamoto, N.; Rogers, M.A.; Abe-Dohmae, S.; Fujimoto, T.; Chang, C.C.Y.; Ishigami, M.; Kishimoto, T.; Kobayashi, T.; Ueda, K.; et al. Deficiency in the Lipid Exporter ABCA1 Impairs Retrograde Sterol Movement and Disrupts Sterol Sensing at the Endoplasmic Reticulum. J. Biol. Chem. 2015, 290, 23464–23477.
  13. Das, A.; Brown, M.S.; Anderson, D.D.; Goldstein, J.L.; Radhakrishnan, A. Three Pools of Plasma Membrane Cholesterol and Their Relation to Cholesterol Homeostasis. eLife 2014, 3, e02882.
  14. Mesmin, B.; Pipalia, N.H.; Lund, F.W.; Ramlall, T.F.; Sokolov, A.; Eliezer, D.; Maxfield, F.R. STARD4 Abundance Regulates Sterol Transport and Sensing. Mol. Biol. Cell 2011, 22, 4004–4015.
  15. Garbarino, J.; Pan, M.; Chin, H.F.; Lund, F.W.; Maxfield, F.R.; Breslow, J.L. STARD4 Knockdown in HepG2 Cells Disrupts Cholesterol Trafficking Associated with the Plasma Membrane, ER, and ERC. J. Lipid Res. 2012, 53, 2716–2725.
  16. Sandhu, J.; Li, S.; Fairall, L.; Pfisterer, S.G.; Gurnett, J.E.; Xiao, X.; Weston, T.A.; Vashi, D.; Ferrari, A.; Orozco, J.L.; et al. Aster Proteins Facilitate Nonvesicular Plasma Membrane to ER Cholesterol Transport in Mammalian Cells. Cell 2018, 175, 514–529.e20.
  17. Naito, T.; Ercan, B.; Krshnan, L.; Triebl, A.; Koh, D.H.Z.; Wei, F.-Y.; Tomizawa, K.; Torta, F.T.; Wenk, M.R.; Saheki, Y. Movement of Accessible Plasma Membrane Cholesterol by the GRAMD1 Lipid Transfer Protein Complex. eLife 2019, 8, e51401.
  18. Yamazaki, T.; Chang, T.-Y.; Haass, C.; Ihara, Y. Accumulation and Aggregation of Amyloid β-Protein in Late Endosomes of Niemann-Pick Type C Cells. J. Biol. Chem. 2001, 276, 4454–4460.
  19. Wiȩckowska-Gacek, A.; Mietelska-Porowska, A.; Chutorański, D.; Wydrych, M.; Długosz, J.; Wojda, U. Western Diet Induces Impairment of Liver-Brain Axis Accelerating Neuroinflammation and Amyloid Pathology in Alzheimer’s Disease. Front. Aging Neurosci. 2021, 13, 654509.
  20. Wang, J.; Li, Y.; Lai, K.; Zhong, Q.; Demin, K.A.; Kalueff, A.V.; Song, C. High-Glucose/High-Cholesterol Diet in Zebrafish Evokes Diabetic and Affective Pathogenesis: The Role of Peripheral and Central Inflammation, Microglia and Apoptosis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020, 96, 109752.
  21. Zhang, J.; Liu, Q. Cholesterol Metabolism and Homeostasis in the Brain. Protein Cell 2015, 6, 254–264.
  22. Liu, J.-P.; Tang, Y.; Zhou, S.; Toh, B.H.; McLean, C.; Li, H. Cholesterol Involvement in the Pathogenesis of Neurodegenerative Diseases. Mol. Cell. Neurosci. 2010, 43, 33–42.
  23. Puglielli, L.; Tanzi, R.E.; Kovacs, D.M. Alzheimer’s Disease: The Cholesterol Connection. Nat. Neurosci. 2003, 6, 345–351.
  24. Leng, F.; Edison, P. Neuroinflammation and Microglial Activation in Alzheimer Disease: Where Do We Go from Here? Nat. Rev. Neurol. 2021, 17, 157–172.
  25. Hansen, D.V.; Hanson, J.E.; Sheng, M. Microglia in Alzheimer’s Disease. J. Cell Biol. 2018, 217, 459–472.
  26. Mrak, R.E. Microglia in Alzheimer Brain: A Neuropathological Perspective. Int. J. Alzheimers Dis. 2012, 2012, 165021.
  27. Sarlus, H.; Heneka, M.T. Microglia in Alzheimer’s Disease. J. Clin. Investig. 2017, 127, 3240–3249.
  28. Streit, W.J. Microglia and Alzheimer’s Disease Pathogenesis. J. Neurosci. Res. 2004, 77, 1–8.
  29. Giulian, D. Microglia and the Immune Pathology of Alzheimer Disease. Am. J. Hum. Genet. 1999, 65, 13–18.
  30. Escott-Price, V.; Bellenguez, C.; Wang, L.-S.; Choi, S.-H.; Harold, D.; Jones, L.; Holmans, P.; Gerrish, A.; Vedernikov, A.; Richards, A.; et al. Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer’s Disease. PLoS ONE 2014, 9, e94661.
  31. Jansen, I.E.; Savage, J.E.; Watanabe, K.; Bryois, J.; Williams, D.M.; Steinberg, S.; Sealock, J.; Karlsson, I.K.; Hägg, S.; Athanasiu, L.; et al. Genome-Wide Meta-Analysis Identifies New Loci and Functional Pathways Influencing Alzheimer’s Disease Risk. Nat. Genet. 2019, 51, 404–413.
  32. Bellenguez, C.; Küçükali, F.; Jansen, I.E.; Kleineidam, L.; Moreno-Grau, S.; Amin, N.; Naj, A.C.; Campos-Martin, R.; Grenier-Boley, B.; Andrade, V.; et al. New Insights into the Genetic Etiology of Alzheimer’s Disease and Related Dementias. Nat. Genet. 2022, 54, 412–436.
  33. Bis, J.C.; Jian, X.; Kunkle, B.W.; Chen, Y.; Hamilton-Nelson, K.L.; Bush, W.S.; Salerno, W.J.; Lancour, D.; Ma, Y.; Renton, A.E.; et al. Whole Exome Sequencing Study Identifies Novel Rare and Common Alzheimer’s-Associated Variants Involved in Immune Response and Transcriptional Regulation. Mol. Psychiatry 2020, 25, 1859–1875.
  34. Karch, C.M.; Goate, A.M. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biol. Psychiatry 2015, 77, 43–51.
  35. Li, Q.; Barres, B.A. Microglia and Macrophages in Brain Homeostasis and Disease. Nat. Rev. Immunol. 2018, 18, 225–242.
  36. Schlegelmilch, T.; Henke, K.; Peri, F. Microglia in the Developing Brain: From Immunity to Behaviour. Curr. Opin. Neurobiol. 2011, 21, 5–10.
  37. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo. Science 2005, 308, 1314–1318.
  38. Peri, F.; Nüsslein-Volhard, C. Live Imaging of Neuronal Degradation by Microglia Reveals a Role for V0-ATPase A1 in Phagosomal Fusion In Vivo. Cell 2008, 133, 916–927.
  39. Hammond, T.R.; Dufort, C.; Dissing-Olesen, L.; Giera, S.; Young, A.; Wysoker, A.; Walker, A.J.; Gergits, F.; Segel, M.; Nemesh, J.; et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 2019, 50, 253–271.e6.
  40. Li, Q.; Cheng, Z.; Zhou, L.; Darmanis, S.; Neff, N.F.; Okamoto, J.; Gulati, G.; Bennett, M.L.; Sun, L.O.; Clarke, L.E.; et al. Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 2019, 101, 207–223.e10.
  41. Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.; Baruch, K.; Lara-Astaiso, D.; Toth, B.; et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell 2017, 169, 1276–1290.e17.
  42. Wu, S.; Nguyen, L.T.M.; Pan, H.; Hassan, S.; Dai, Y.; Xu, J.; Wen, Z. Two Phenotypically and Functionally Distinct Microglial Populations in Adult Zebrafish. Sci. Adv. 2020, 6, eabd1160.
  43. Olah, M.; Menon, V.; Habib, N.; Taga, M.F.; Ma, Y.; Yung, C.J.; Cimpean, M.; Khairallah, A.; Coronas-Samano, G.; Sankowski, R.; et al. Single Cell RNA Sequencing of Human Microglia Uncovers a Subset Associated with Alzheimer’s Disease. Nat. Commun. 2020, 11, 6129.
  44. Dawson, G. Measuring Brain Lipids. Biochim. Biophys. Acta BBA—Mol. Cell Biol. Lipids 2015, 1851, 1026–1039.
  45. Cabral, D.J.; Small, D.M. Physical Chemistry of Bile. In Comprehensive Physiology; Terjung, R., Ed.; Wiley: Hoboken, NJ, USA, 1989; pp. 621–662.
  46. von Eckardstein, A.; Nofer, J.-R.; Assmann, G. High Density Lipoproteins and Arteriosclerosis: Role of Cholesterol Efflux and Reverse Cholesterol Transport. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 13–27.
  47. Feingold, K.R. Lipid and Lipoprotein Metabolism. Endocrinol. Metab. Clin. N. Am. 2022, 51, 437–458.
  48. Goldstein, J.L.; DeBose-Boyd, R.A.; Brown, M.S. Protein Sensors for Membrane Sterols. Cell 2006, 124, 35–46.
  49. Radhakrishnan, A.; Goldstein, J.L.; McDonald, J.G.; Brown, M.S. Switch-like Control of SREBP-2 Transport Triggered by Small Changes in ER Cholesterol: A Delicate Balance. Cell Metab. 2008, 8, 512–521.
  50. Yokoyama, C.; Wang, X.; Briggs, M.R.; Admon, A.; Wu, J.; Hua, X.; Goldstein, J.L.; Brown, M.S. SREBP-1, a Basic-Helix-Loop-Helix-Leucine Zipper Protein That Controls Transcription of the Low Density Lipoprotein Receptor Gene. Cell 1993, 75, 187–197.
  51. Fitzgerald, M.L.; Mendez, A.J.; Moore, K.J.; Andersson, L.P.; Panjeton, H.A.; Freeman, M.W. ATP-Binding Cassette Transporter A1 Contains an NH2-Terminal Signal Anchor Sequence That Translocates the Protein’s First Hydrophilic Domain to the Exoplasmic Space. J. Biol. Chem. 2001, 276, 15137–15145.
  52. Oram, J.F. HDL Apolipoproteins and ABCA1: Partners in the Removal of Excess Cellular Cholesterol. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 720–727.
  53. Dean, M.; Hamon, Y.; Chimini, G. The Human ATP-Binding Cassette (ABC) Transporter Superfamily. J. Lipid Res. 2001, 42, 1007–1017.
  54. Fawcett, D.W. An Atlas of Fine Structure: The Cell, Its Organelles, and Inclusions; Saunders: Philadelphia, PA, USA, 1966.
  55. Farese, R.V.; Walther, T.C. Lipid Droplets Finally Get a Little R-E-S-P-E-C-T. Cell 2009, 139, 855–860.
  56. Marschallinger, J.; Iram, T.; Zardeneta, M.; Lee, S.E.; Lehallier, B.; Haney, M.S.; Pluvinage, J.V.; Mathur, V.; Hahn, O.; Morgens, D.W.; et al. Lipid-Droplet-Accumulating Microglia Represent a Dysfunctional and Proinflammatory State in the Aging Brain. Nat. Neurosci. 2020, 23, 194–208.
  57. Colombo, A.; Dinkel, L.; Müller, S.A.; Sebastian Monasor, L.; Schifferer, M.; Cantuti-Castelvetri, L.; König, J.; Vidatic, L.; Bremova-Ertl, T.; Lieberman, A.P.; et al. Loss of NPC1 Enhances Phagocytic Uptake and Impairs Lipid Trafficking in Microglia. Nat. Commun. 2021, 12, 1158.
  58. Hanisch, U.-K.; Kettenmann, H. Microglia: Active Sensor and Versatile Effector Cells in the Normal and Pathologic Brain. Nat. Neurosci. 2007, 10, 1387–1394.
  59. O’Neil, S.M.; Hans, E.E.; Jiang, S.; Wangler, L.M.; Godbout, J.P. Astrocyte Immunosenescence and Deficits in Interleukin 10 Signaling in the Aged Brain Disrupt the Regulation of Microglia Following Innate Immune Activation. Glia 2022, 70, 913–934.
  60. Colonna, M.; Butovsky, O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu. Rev. Immunol. 2017, 35, 441–468.
  61. Guglielmotto, M.; Monteleone, D.; Piras, A.; Valsecchi, V.; Tropiano, M.; Ariano, S.; Fornaro, M.; Vercelli, A.; Puyal, J.; Arancio, O.; et al. Aβ1-42 Monomers or Oligomers Have Different Effects on Autophagy and Apoptosis. Autophagy 2014, 10, 1827–1843.
  62. Baerends, E.; Soud, K.; Folke, J.; Pedersen, A.-K.; Henmar, S.; Konrad, L.; Lycas, M.D.; Mori, Y.; Pakkenberg, B.; Woldbye, D.P.D.; et al. Modeling the Early Stages of Alzheimer’s Disease by Administering Intracerebroventricular Injections of Human Native Aβ Oligomers to Rats. Acta Neuropathol. Commun. 2022, 10, 113.
  63. Tamagno, E.; Bardini, P.; Guglielmotto, M.; Danni, O.; Tabaton, M. The Various Aggregation States of β-Amyloid 1–42 Mediate Different Effects on Oxidative Stress, Neurodegeneration, and BACE-1 Expression. Free Radic. Biol. Med. 2006, 41, 202–212.
  64. Brown, A.J.; Jessup, W. Oxysterols: Sources, Cellular Storage and Metabolism, and New Insights into Their Roles in Cholesterol Homeostasis. Mol. Asp. Med. 2009, 30, 111–122.
  65. Gamba, P.; Testa, G.; Gargiulo, S.; Staurenghi, E.; Poli, G.; Leonarduzzi, G. Oxidized Cholesterol as the Driving Force behind the Development of Alzheimer’s Disease. Front. Aging Neurosci. 2015, 7, 119.
  66. Chang, J.Y.; Chavis, J.A.; Liu, L.-Z.; Drew, P.D. Cholesterol Oxides Induce Programmed Cell Death in Microglial Cells. Biochem. Biophys. Res. Commun. 1998, 249, 817–821.
  67. Liu, J.; Liu, Y.; Chen, J.; Hu, C.; Teng, M.; Jiao, K.; Shen, Z.; Zhu, D.; Yue, J.; Li, Z.; et al. The ROS-Mediated Activation of IL-6/STAT3 Signaling Pathway Is Involved in the 27-Hydroxycholesterol-Induced Cellular Senescence in Nerve Cells. Toxicol. Vitr. 2017, 45, 10–18.
  68. Simpson, D.S.A.; Oliver, P.L. ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. Antioxidants 2020, 9, 743.
  69. Olsen, B.N.; Schlesinger, P.H.; Baker, N.A. Perturbations of Membrane Structure by Cholesterol and Cholesterol Derivatives Are Determined by Sterol Orientation. J. Am. Chem. Soc. 2009, 131, 4854–4865.
  70. Kauffman, J.M.; Westerman, P.W.; Carey, M.C. Fluorocholesterols, in Contrast to Hydroxycholesterols, Exhibit Interfacial Properties Similar to Cholesterol. J. Lipid Res. 2000, 41, 991–1003.
  71. Holmes, R.P.; Yoss, N.L. 25-Hydroxysterols Increase the Permeability of Liposomes to Ca2+ and Other Cations. Biochim. Biophys. Acta 1984, 770, 15–21.
  72. Theunissen, J.J.; Jackson, R.L.; Kempen, H.J.; Demel, R.A. Membrane Properties of Oxysterols. Interfacial Orientation, Influence on Membrane Permeability and Redistribution between Membranes. Biochim. Biophys. Acta 1986, 860, 66–74.
  73. Appelqvist, H.; Wäster, P.; Kågedal, K.; Öllinger, K. The Lysosome: From Waste Bag to Potential Therapeutic Target. J. Mol. Cell Biol. 2013, 5, 214–226.
  74. Gosselet, F.; Saint-Pol, J.; Fenart, L. Effects of Oxysterols on the Blood–Brain Barrier: Implications for Alzheimer’s Disease. Biochem. Biophys. Res. Commun. 2014, 446, 687–691.
  75. Gamba, P.; Leonarduzzi, G.; Tamagno, E.; Guglielmotto, M.; Testa, G.; Sottero, B.; Gargiulo, S.; Biasi, F.; Mauro, A.; Viña, J.; et al. Interaction between 24-Hydroxycholesterol, Oxidative Stress, and Amyloid-β in Amplifying Neuronal Damage in Alzheimer’s Disease: Three Partners in Crime: 24-Hydroxycholesterol Potentiates Amyloid-Beta Neurotoxicity. Aging Cell 2011, 10, 403–417.
  76. Trompier, D.; Vejux, A.; Zarrouk, A.; Gondcaille, C.; Geillon, F.; Nury, T.; Savary, S.; Lizard, G. Brain Peroxisomes. Biochimie 2014, 98, 102–110.
  77. Nury, T.; Yammine, A.; Menetrier, F.; Zarrouk, A.; Vejux, A.; Lizard, G. 7-Ketocholesterol- and 7β-Hydroxycholesterol-Induced Peroxisomal Disorders in Glial, Microglial and Neuronal Cells: Potential Role in Neurodegeneration: 7-Ketocholesterol and 7β-Hydroxycholesterol-Induced Peroxisomal Disorders and Neurodegeneration. In Peroxisome Biology: Experimental Models, Peroxisomal Disorders and Neurological Diseases; Lizard, G., Ed.; Advances in Experimental Medicine and Biology: London, UK; Springer International Publishing: Cham, Switzerland, 2020; Volume 1299, pp. 31–41.
  78. Diestel, A.; Aktas, O.; Hackel, D.; Häke, I.; Meier, S.; Raine, C.S.; Nitsch, R.; Zipp, F.; Ullrich, O. Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation. J. Exp. Med. 2003, 198, 1729–1740.
  79. Loving, B.A.; Tang, M.; Neal, M.C.; Gorkhali, S.; Murphy, R.; Eckel, R.H.; Bruce, K.D. Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation. Cells 2021, 10, 198.
  80. Pascual-García, M.; Rué, L.; León, T.; Julve, J.; Carbó, J.M.; Matalonga, J.; Auer, H.; Celada, A.; Escolà-Gil, J.C.; Steffensen, K.R.; et al. Reciprocal Negative Cross-Talk between Liver X Receptors (LXRs) and STAT1: Effects on IFN-γ–Induced Inflammatory Responses and LXR-Dependent Gene Expression. J. Immunol. 2013, 190, 6520–6532.
  81. Berghoff, S.A.; Spieth, L.; Sun, T.; Hosang, L.; Schlaphoff, L.; Depp, C.; Düking, T.; Winchenbach, J.; Neuber, J.; Ewers, D.; et al. Microglia Facilitate Repair of Demyelinated Lesions via Post-Squalene Sterol Synthesis. Nat. Neurosci. 2021, 24, 47–60.
  82. Račková, L. Cholesterol Load of Microglia: Contribution of Membrane Architecture Changes to Neurotoxic Power? Arch. Biochem. Biophys. 2013, 537, 91–103.
  83. Ciesielska, A.; Matyjek, M.; Kwiatkowska, K. TLR4 and CD14 Trafficking and Its Influence on LPS-Induced pro-Inflammatory Signaling. Cell. Mol. Life Sci. 2021, 78, 1233–1261.
  84. Qiao, X.; Cummins, D.J.; Paul, S.M. Neuroinflammation-Induced Acceleration of Amyloid Deposition in the APP V717F Transgenic Mouse: Neuroinflammation-Induced Acceleration of Amyloid Deposition. Eur. J. Neurosci. 2001, 14, 474–482.
  85. Sheng, J. Lipopolysaccharide-Induced-Neuroinflammation Increases Intracellular Accumulation of Amyloid Precursor Protein and Amyloid β Peptide in APPswe Transgenic Mice. Neurobiol. Dis. 2003, 14, 133–145.
  86. Chen, Y.; Yin, M.; Cao, X.; Hu, G.; Xiao, M. Pro- and Anti-Inflammatory Effects of High Cholesterol Diet on Aged Brain. Aging Dis. 2018, 9, 374.
  87. Duong, M.T.; Nasrallah, I.M.; Wolk, D.A.; Chang, C.C.Y.; Chang, T.-Y. Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy. Front. Aging Neurosci. 2021, 13, 647990.
  88. Famer, D.; Wahlund, L.-O.; Crisby, M. Rosuvastatin Reduces Microglia in the Brain of Wild Type and ApoE Knockout Mice on a High Cholesterol Diet, Implications for Prevention of Stroke and AD. Biochem. Biophys. Res. Commun. 2010, 402, 367–372.
  89. Angelopoulou, E.; Paudel, Y.N.; Papageorgiou, S.G.; Piperi, C. APOE Genotype and Alzheimer’s Disease: The Influence of Lifestyle and Environmental Factors. ACS Chem. Neurosci. 2021, 12, 2749–2764.
  90. Minagawa, H.; Gong, J.-S.; Jung, C.-G.; Watanabe, A.; Lund-Katz, S.; Phillips, M.C.; Saito, H.; Michikawa, M. Mechanism Underlying Apolipoprotein E (ApoE) Isoform-Dependent Lipid Efflux from Neural Cells in Culture. J. Neurosci. Res. 2009, 87, 2498–2508.
  91. Iannucci, J.; Sen, A.; Grammas, P. Isoform-Specific Effects of Apolipoprotein E on Markers of Inflammation and Toxicity in Brain Glia and Neuronal Cells In Vitro. Curr. Issues Mol. Biol. 2021, 43, 215–225.
  92. Cantuti-Castelvetri, L.; Fitzner, D.; Bosch-Queralt, M.; Weil, M.-T.; Su, M.; Sen, P.; Ruhwedel, T.; Mitkovski, M.; Trendelenburg, G.; Lütjohann, D.; et al. Defective Cholesterol Clearance Limits Remyelination in the Aged Central Nervous System. Science 2018, 359, 684–688.
  93. Churchward, M.A.; Todd, K.G. Statin Treatment Affects Cytokine Release and Phagocytic Activity in Primary Cultured Microglia through Two Separable Mechanisms. Mol. Brain 2014, 7, 85.
  94. Yeh, F.L.; Wang, Y.; Tom, I.; Gonzalez, L.C.; Sheng, M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 2016, 91, 328–340.
  95. Ulland, T.K.; Colonna, M. TREM2—A Key Player in Microglial Biology and Alzheimer Disease. Nat. Rev. Neurol. 2018, 14, 667–675.
  96. Nugent, A.A.; Lin, K.; van Lengerich, B.; Lianoglou, S.; Przybyla, L.; Davis, S.S.; Llapashtica, C.; Wang, J.; Kim, D.J.; Xia, D.; et al. TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 2020, 105, 837–854.e9.
  97. Oram, J.F.; Heinecke, J.W. ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects against Cardiovascular Disease. Physiol. Rev. 2005, 85, 1343–1372.
  98. Karasinska, J.M.; de Haan, W.; Franciosi, S.; Ruddle, P.; Fan, J.; Kruit, J.K.; Stukas, S.; Lütjohann, D.; Gutmann, D.H.; Wellington, C.L.; et al. ABCA1 Influences Neuroinflammation and Neuronal Death. Neurobiol. Dis. 2013, 54, 445–455.
  99. Tanaka, N.; Abe-Dohmae, S.; Iwamoto, N.; Fitzgerald, M.L.; Yokoyama, S. Helical Apolipoproteins of High-Density Lipoprotein Enhance Phagocytosis by Stabilizing ATP-Binding Cassette Transporter A7. J. Lipid Res. 2010, 51, 2591–2599.
  100. Aikawa, T.; Holm, M.-L.; Kanekiyo, T. ABCA7 and Pathogenic Pathways of Alzheimer’s Disease. Brain Sci. 2018, 8, 27.
  101. Dai, W.; Yao, R.-M.; Mi, T.-Y.; Zhang, L.-M.; Wu, H.; Cheng, J.-B.; Li, Y.-F. Cognition-Enhancing Effect of YL-IPA08, a Potent Ligand for the Translocator Protein (18 KDa) in the 5 × FAD Transgenic Mouse Model of Alzheimer’s Pathology. J. Psychopharmacol. 2022, 36, 1176–1187.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback